Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 8 participants, all of whom completed the study — none dropped out. The trial was looking at a combination of two medicines, imatinib (taken by mouth) and gemcitabine (given through a drip), in people with recurrent or persistent ovarian or primary peritoneal cancer who had already received at least one prior chemotherapy treatment. The main things being measured were how many participants went at least six months without their disease getting worse, and how often and how severely side effects occurred. Secondary measurements included tumour response rates and overall survival. The reported data shows that, of the 8 participants, none reached the six-month mark without their disease progressing — meaning 0 out of 8 met that primary goal. For side effects, the reported data shows 3 participants experienced one level of adverse effect, 1 experienced another level, and 1 experienced a further level; however, the severity categories for these numbers were not clearly labelled in the submitted data, so a more detailed breakdown cannot be provided here. On the secondary measures, the reported data shows that 0 participants had a partial tumour response, and 0 participants had a combined complete or partial response. The reported median overall survival — that is, the midpoint survival time across participants — was 9 months. The investigators noted that the study was stopped after 8 participants, and because of the small number, they were unable to carry out the planned analysis of factors that might influence outcomes, so those results were not reported. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are 18 years old or older
- You have been diagnosed with ovarian cancer or primary peritoneal cancer, confirmed by a tissue sample (biopsy), including types such as mucinous, serous, endometrioid, clear cell, or undifferentiated tumors
- Your cancer can be measured on scans or imaging (at least one visible area of disease)
- Your cancer came back after you previously received at least one chemotherapy treatment that included a platinum-based drug (such as carboplatin or cisplatin)
- Your general health and ability to carry out daily activities meets a certain minimum level (confirm with trial site)
- Your liver, kidneys, and blood cell counts are within acceptable ranges based on blood tests (confirm with trial site)
- If you could still become pregnant, you must have a negative pregnancy test within 7 days before starting the study drug, and you must agree to use an effective barrier method of birth control during the study and for up to 3 months after stopping the study drug
- You are willing and able to sign a consent form agreeing to take part
- You must be eligible to receive care at a military medical treatment facility
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have previously been treated with a drug called Gemzar (gemcitabine)
- You have taken part in another clinical trial or received an experimental drug within the last 28 days
- You have had another type of cancer within the past 5 years, unless it was a basal cell skin cancer, cervical carcinoma in situ, or a cancer that is not active and does not need treatment
- You have serious heart problems classified as Grade III or IV (confirm with trial site)
- You are currently pregnant or breastfeeding
- You have a severe or uncontrolled medical condition, such as uncontrolled diabetes, uncontrolled chronic kidney disease, or an active uncontrolled infection
- You have cancer that has spread to the brain and has not been treated or is getting worse
- You have a known chronic liver disease, such as chronic hepatitis or cirrhosis
- You have been diagnosed with HIV
- You have received chemotherapy within the last 4 weeks (or 6 weeks for certain specific chemotherapy drugs), unless your cancer is rapidly worsening
- You have previously had radiation therapy covering 25% or more of your bone marrow
- You have had major surgery within the last 2 weeks
- You have a history of not following medical treatment plans, or you are unable to give reliable informed consent
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
The Cystostatic, Anti-tumor Activity of the Combination of Gleevec and Gemzar Via Progression-free Survival for at Least Six Months in Patients With Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma.; To Determine the Safety and Tolerability Via Frequency and Severity of Adverse Effect of Combination Gleevec and Gemzar in This Cohort of Patients as Assessed Byt Common Toxicity Criteria
Other options
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.